BNP Paribas Financial Markets Raises Stock Position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)

BNP Paribas Financial Markets lifted its holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) by 2,166.4% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 27,197 shares of the company’s stock after buying an additional 25,997 shares during the period. BNP Paribas Financial Markets’ holdings in Kyverna Therapeutics were worth $133,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Deerfield Management Company L.P. Series C boosted its stake in Kyverna Therapeutics by 35.6% during the second quarter. Deerfield Management Company L.P. Series C now owns 1,983,000 shares of the company’s stock worth $14,872,000 after buying an additional 520,663 shares during the period. Novo Holdings A S raised its position in Kyverna Therapeutics by 5.7% in the 3rd quarter. Novo Holdings A S now owns 1,850,000 shares of the company’s stock worth $9,046,000 after purchasing an additional 100,000 shares during the period. Millennium Management LLC raised its position in Kyverna Therapeutics by 32.8% in the 2nd quarter. Millennium Management LLC now owns 923,082 shares of the company’s stock worth $6,923,000 after purchasing an additional 227,988 shares during the period. Great Point Partners LLC lifted its stake in Kyverna Therapeutics by 232.8% in the second quarter. Great Point Partners LLC now owns 499,152 shares of the company’s stock worth $3,744,000 after purchasing an additional 349,152 shares during the last quarter. Finally, MBB Public Markets I LLC bought a new position in shares of Kyverna Therapeutics during the second quarter valued at approximately $3,076,000. 18.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on KYTX shares. Rodman & Renshaw started coverage on Kyverna Therapeutics in a report on Wednesday, October 9th. They set a “buy” rating and a $16.00 price objective for the company. HC Wainwright cut their price target on shares of Kyverna Therapeutics from $7.00 to $6.00 and set a “neutral” rating on the stock in a report on Wednesday, November 20th. RODMAN&RENSHAW upgraded shares of Kyverna Therapeutics to a “strong-buy” rating in a report on Wednesday, October 9th. Wells Fargo & Company dropped their target price on shares of Kyverna Therapeutics from $44.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday, November 15th. Finally, UBS Group started coverage on shares of Kyverna Therapeutics in a research note on Thursday, October 10th. They set a “buy” rating and a $13.00 price target for the company. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Kyverna Therapeutics has a consensus rating of “Buy” and a consensus price target of $25.71.

Kyverna Therapeutics Trading Down 9.5 %

NASDAQ KYTX opened at $3.79 on Thursday. The firm’s 50 day moving average price is $4.97 and its 200-day moving average price is $6.98. Kyverna Therapeutics, Inc. has a 52-week low of $3.77 and a 52-week high of $35.06.

Kyverna Therapeutics (NASDAQ:KYTX) last released its quarterly earnings results on Wednesday, November 13th. The company reported ($0.80) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.01. The firm had revenue of $0.01 million during the quarter. As a group, research analysts expect that Kyverna Therapeutics, Inc. will post -3.29 earnings per share for the current fiscal year.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.